Dr. Siddhartha H. Devarakonda, MD

Medicare patients and services

Medicare patients, 2024

114

Services billed

809

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 124 payments worth $125,021 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Washington →

Industry-funded research

Named as a principal investigator on 15 industry-funded studies in 2025, from 11 companies. The companies reported $2,238,974 in research payments for these studies, mostly to the institutions running them.

• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  Eli Lilly and Company · Recruiting · NCT06119581
• A phase 1 study of SGNB6A in advanced solid tumors
  Pfizer Inc.
• A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
  Janssen Research & Development, LLC
• A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors
  E.r. Squibb & Sons, L.l.c.
• Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, …
  Boehringer Ingelheim Pharma GmbH & Co.kg
• Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, …
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment Wi…
  Genmab A/s
• Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-lin…
  E.r. Squibb & Sons, L.l.c.
• A phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell…
  AstraZeneca UK Limited
• A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Seattle

• Vyshak Alva Venur, M.D
• Frederick R. Appelbaum
• Anthony L. Back, MD
• Charles M. Bagley JR., MD
• Christina S. Baik, M.D.
• Merav Bar, MD
• Shailender Bhatia, MD
• Marie Bleakley, MD